Aspartic Acid

Aspartic Acid

SCHEMBL4390865

CC(C)C[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)O.N[C@@H](CC(=O)O)C(=O)O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SSTR1SSTR2SSTR3SSTR5

The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 5/20 0.52
FOLH1 Q04609 7/20 0.50
PTGS1 P23219 1/20 0.49
GSTK1 Q9Y2Q3 1/20 0.49
SLC7A5 Q01650 1/20 0.47
GLO1 Q04760 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LAP3 P28838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aspartic Acid SCHEMBL4390861 1.00 NOD1 (0.52) NOD1FOLH1PTGS1GSTK1SLC7A5
SCHEMBL234160 0.93 NOD1 (0.58) NOD1FOLH1PTGS1GSTK1SLC7A5
SCHEMBL13585300 0.93 NOD1 (0.58) NOD1FOLH1PTGS1GSTK1SLC7A5
SCHEMBL234161 0.93 NOD1 (0.58) NOD1FOLH1PTGS1GSTK1SLC7A5
SCHEMBL13585297 0.93 NOD1 (0.58) NOD1FOLH1PTGS1GSTK1SLC7A5
SCHEMBL9628017 0.93 NOD1 (0.58) NOD1FOLH1PTGS1GSTK1SLC7A5
D-Glutamate SCHEMBL4393018 0.91 FOLH1 (0.60) NOD1FOLH1PTGS1GSTK1GLO1
Glutamic Acid SCHEMBL4393021 0.91 FOLH1 (0.60) NOD1FOLH1PTGS1GSTK1GLO1
Glutamine SCHEMBL4395724 0.87 KMT2A (0.56) NOD1FOLH1PTGS1GSTK1SLC7A5
Glutamine SCHEMBL4395718 0.87 KMT2A (0.56) NOD1FOLH1PTGS1GSTK1SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10175233-B2 Biomarkers for cardiovascular diseases and methods using the same METABOLON, INC. (US) 2019-01-08 US disclosed
US-20160178620-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2016-06-23 US disclosed
US-9250225-B2 Biomarkers for insulin resistance and methods using the same METABOLON, INC. (US) 2016-02-02 US disclosed
US-20150005195-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2015-01-01 US disclosed
US-8809008-B2 Biomarkers for impaired glucose tolerance and methods using the same METABOLON, INC. (US) 2014-08-19 US disclosed
US-20130338031-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2013-12-19 US disclosed
EP-2164977-B1 BIOMARKERS FOR PRE-DIABETES AND METHODS USING THE SAME METABOLON INC (US) 2013-10-30 EP disclosed
US-8546098-B2 Biomarkers for monitoring insulin resistance and methods using the same METABOLON, INC. (US) 2013-10-01 US disclosed
US-20120208215-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. (US) 2012-08-16 US disclosed
US-8187830-B2 Method for determining insulin sensitivity with biomarkers METABOLON, INC. (US) 2012-05-29 US disclosed
US-20090155826-A1 Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same METABOLON, INC. (US) 2009-06-18 US disclosed